The study, by investigators from the Casey Eye Institute, Oregon Health and Science University, supported the use of at-home tests during teleophthalmology care, an important point considering the significant drop in in-person VA evaluations during the pandemic.
April is Presbyopia Awareness Month. Brieann K. Adair, OD, of NYU Langone Health, speaks with Ophthalmology Times’ Sheryl Stevenson about the importance of Presbyopia awareness, treatment options and more.
The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.
In those first few months, I realized there were so many aspects of real-life, post-residency practice we had never been taught during medical school or residency.
A University of Houston study found that minorities have fewer eye exams, higher instances of disease.
If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.
A separate analysis will be presented at the American Academy of Neurology 2022 Annual Meeting, showing that UPLIZNA reduced pan associated with NMOSD over 3 years.
Treatment options beginning to evolve from traditional therapies
Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation.
Beginning in the 1970s, James J. Salz, MD, was part of a group of ophthalmologists who first inserted intraocular lens implants during cataract surgery.
The American College of Medical Genetics and Genomics Foundation for Genetic and Genomic Medicine grants its Next Generation Fellowship Awards to promising early-career professionals in a range of medical genetics and genomics specialties. The awards were presented at the 2022 ACMG Clinical Genetics Meeting.
The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.
The country’s Ministry of Health has issued infringement notices to two ophthalmologist for seeing patients while unvaccinated.
The MIRA-3 Phase 3 FDA Registration trial for Nyxol met its primary endpoint with 58% of treated subjects returning to baseline pupil diameter at 90 minutes compared to 6% of placebo subjects.
The company’s iCare HOME2 self-tonometer allows patients to collect real-world IOP data at any time.
Assembling a team of experts is key for diagnosis, treatment
Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject in lowering IOP as a standalone treatment option without concomitant cataract surgery.
The EVO/EVO+ Visian Implantable Collamer Lens provides visual freedom independent of contact lenses and glasses.
Mark Packer, MD, shares his perspective on the relationship between ICL implantation or LASIK and retinal detachment.
Assessing cornea status can aid early recognition of disease-related changes
The San Francisco-based company also announces that Raj K. Maturi, MD, is the first PI in the network.
Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.
Investigators theorize that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.
Sponsored Content
Lower doses vs higher ones are equally effective for treating disease
Investigators have questioned the potential for the vascular density to be a biomarker for microvascular abnormalities following COVID-19 and found that longitudinal studies are needed to determine this.
According to the company, VVN001 demonstrated clinical and statistical superiority over vehicle in reducing total and sub-regional corneal fluorescein staining scores.
A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells – a class of neurons located in the retina that are critical for vision.
The company notes that its clinical trial of the light delivery system meets the primary efficacy endpoint, and can offer hope to patients with dry AMD who are experiencing vision loss and currently have limited treatment options.